IGC Pharma (NYSEAMERICAN:IGC) Stock Crosses Above 200-Day Moving Average of $0.00

IGC Pharma, Inc. (NYSEAMERICAN:IGC) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.32. IGC Pharma shares last traded at $0.30, with a volume of 116,736 shares changing hands.

IGC Pharma Stock Down 2.7 %

The stock has a market cap of $18.99 million, a P/E ratio of -1.42 and a beta of 1.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.65 and a current ratio of 2.90.

Hedge Funds Weigh In On IGC Pharma

A number of institutional investors have recently added to or reduced their stakes in IGC. Renaissance Technologies LLC boosted its stake in shares of IGC Pharma by 47.4% during the third quarter. Renaissance Technologies LLC now owns 320,900 shares of the construction company’s stock valued at $138,000 after purchasing an additional 103,151 shares in the last quarter. Vident Investment Advisory LLC raised its stake in IGC Pharma by 66.3% during the first quarter. Vident Investment Advisory LLC now owns 104,011 shares of the construction company’s stock worth $99,000 after buying an additional 41,457 shares during the last quarter. Millennium Management LLC raised its stake in IGC Pharma by 76.2% during the fourth quarter. Millennium Management LLC now owns 144,724 shares of the construction company’s stock worth $46,000 after buying an additional 62,599 shares during the last quarter. Jane Street Group LLC raised its stake in IGC Pharma by 302.6% during the second quarter. Jane Street Group LLC now owns 48,281 shares of the construction company’s stock worth $26,000 after buying an additional 36,290 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its position in shares of IGC Pharma by 211.3% in the 3rd quarter. Commonwealth Equity Services LLC now owns 165,490 shares of the construction company’s stock worth $59,000 after acquiring an additional 112,334 shares in the last quarter. 4.92% of the stock is currently owned by institutional investors and hedge funds.

About IGC Pharma

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.